Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In
  • Log Out

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
  • Log Out
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticlePsoriatic Arthritis

Very Low Disease Activity, DAPSA Remission, and Impact of Disease in a Spanish Population with Psoriatic Arthritis

Ruben Queiro, Juan D. Cañete, Carlos Montilla, Miguel Angel Abad, María Montoro, Susana Gómez and Ana Cábez for the MAAPS Study Group
The Journal of Rheumatology July 2019, 46 (7) 710-715; DOI: https://doi.org/10.3899/jrheum.180460
Ruben Queiro
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ruben Queiro
  • For correspondence: rubenque7@yahoo.es
Juan D. Cañete
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlos Montilla
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miguel Angel Abad
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
María Montoro
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susana Gómez
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ana Cábez
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

This article has a correction. Please see:

  • Errata - September 01, 2019

Abstract

Objective. To examine the grade of agreement between very low disease activity (VLDA) and Disease Activity Index for Psoriatic Arthritis (DAPSA) remission, as well as their association with the effect of the disease as assessed by the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire in patients with psoriatic arthritis in routine clinical practice.

Methods. Posthoc analysis of data from a cross-sectional multicenter study. Patients were included who fulfilled the Classification for Psoriatic Arthritis (CASPAR) criteria with at least 1 year of disease duration and were treated with biological and/or conventional synthetic disease-modifying antirheumatic drugs according to routine clinical practice in Spain. Patients were considered in VLDA if they met 7/7 of the minimal disease activity criteria. DAPSA and clinical (c)DAPSA score ≤ 4 identified remissions.

Results. Of the 227 patients included in the original study, 26 (11.5%), 52 (22.9%), and 65 (28.6%) were in VLDA, DAPSA remission, and cDAPSA remission, respectively. There was a moderate agreement between VLDA and DAPSA remission (κ = 0.52) or cDAPSA remission (κ = 0.42). Patients with VLDA had less effect of the disease as measured by PsAID [mean total score (SD): VLDA 1.1 (1.2); DAPSA remission 1.3 (1.5); cDAPSA remission 1.7 (1.6)]. There was a moderate agreement between DAPSA remission or cDAPSA remission and PsAID < 4 (κ = 0.46 and κ = 0.58 respectively), while poor agreement (κ = 0.18) was found between VLDA and PsAID < 4.

Conclusion. VLDA criteria seem to be more stringent for assessing a status of remission; however, DAPSA remission shows better correlation with a patient-acceptable symptoms state than VLDA does.

Key Indexing Terms:
  • DISEASE ACTIVITY
  • REMISSION
  • PSORIATIC ARTHRITIS
  • DISEASE ACTIVITY CRITERIA

Psoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal disease, usually seronegative for rheumatoid factor and associated with psoriasis, with a prevalence of 0.02–0.42%1 in the general population and 13.8–30% among patients with psoriasis1,2.

The target of therapy in PsA is to reach a state of remission or at least minimal disease activity (MDA). Measuring disease activity has been a challenge owing to the diverse manifestations of the disease, including the skin and the musculoskeletal system3. Currently, different composite indices have been developed specifically for PsA, most focusing on multiple domains considered important to assess the disease activity states4. However, few data have been published on comparing these measures5.

In 2010, Coates, et al6 developed a composite outcome measure as a target of treatment for patients with PsA that encompasses skin, enthesitis, tender and swollen joint counts, and patient-reported domains [pain, the Health Assessment Questionnaire (HAQ), and global disease activity]. These criteria for MDA were validated using interventional trial data7 and could be a reliable target for anti-tumor necrosis factor-α (anti-TNF-α) therapy8,9,10. The same authors developed a more stringent definition of remission, in which all MDA 7/7 criteria (very low disease activity; VLDA) had to be satisfied3.

Previously, Schoels, et al11 proposed the remission criteria for the Disease Activity Index for Psoriatic Arthritis (DAPSA), which can be calculated with or without C-reactive protein [CRP; clinical DAPSA (cDAPSA)] and includes tender and swollen joint counts, and patient-reported pain and global disease activity scores.

It is well known that PsA has a considerable effect on patients’ lives12. Patients with PsA experience significant disability and reduced quality of life, resulting from the emotional distress and functional impairment associated with psoriatic skin lesions, as well as arthritic joints10,13. Gossec, et al have developed and validated the PsA Impact of Disease (PsAID) questionnaire, which can be used to calculate a score reflecting the effect of PsA on patients’ lives14. The PsAID questionnaire assessed 12 health and psychological domains, ranging from pain or physical activity, to anxiety or embarrassment. Scores lower than 4 identify a patient-acceptable symptoms state.

The aims of the present posthoc analysis were to examine the grade of agreement relationship between VLDA and DAPSA remission, as well as their association with the effect of the disease as assessed by the PsAID questionnaire in patients with PsA seen in routine clinical practice.

MATERIALS AND METHODS

This was a posthoc analysis of data from an observational, multicenter, cross-sectional, and retrospective study carried out at 25 rheumatology outpatient clinics in the whole of Spain15.

The study included outpatients of both sexes over 18 years of age diagnosed with PsA according to the Classification for Psoriatic Arthritis (CASPAR) criteria16, with at least 1 year of disease duration, with hand and foot radiological tests carried out during the 6 months prior to the study visit, and under treatment with biological and/or conventional synthetic disease-modifying antirheumatic drugs (csDMARD).

All patients provided their informed written consent to publish the material. In accordance with the Spanish recommendations, the study was approved by the Clinical Research Ethics Committee of La Fe Hospital [ref number: FPNT-07-14-EO (C)] and was conducted in accordance with the principles contained in the Declaration of Helsinki for studies in humans.

Data were collected between May 2014 and February 2015 at the single study visit. Patient data collection included demographics and clinical characteristics15. Patients completed the self-reported PsAID questionnaire14.

Patients were considered in VLDA when they met all MDA 7/7 criteria proposed by Coates, et al3,6: tender joint count ≤ 1; swollen joint count ≤ 1; Psoriasis Area and Severity Index score ≤ 1 or body surface area ≤ 3%; patient pain visual analog scale (VAS) score ≤ 15; patient global disease activity VAS score ≤ 20; HAQ score ≤ 0.5; and tender entheseal points ≤ 1.

DAPSA remission was defined according to Schoels, et al11,17. DAPSA score was calculated by adding the number of tender and swollen joints, VAS pain, patient’s global assessment (PtGA), and CRP (mg/dl). The cDAPSA was calculated without the contribution of CRP. DAPSA and cDAPSA score ≤ 4 identified remissions11.

The PsAID questionnaire 14 reflects the impact of PsA from the patient’s perspective. It is composed of 12 physical and psychological domains. Each domain is rated from 0 to 10 with a different weighting. Total score is divided by 20. The final score has a range from 0 (best status) to 10 (worst status) with a cutoff of 4. PsAID score < 4 identified patient-acceptable symptoms state.

Statistical methodology

A descriptive statistical analysis of all the variables was performed, including central tendency and dispersion measures for continuous variables, and absolute and relative frequencies for categorical variables. Student t test, Mann-Whitney U test, or Kruskall-Wallis H test were used to compare quantitative variables, and Pearson chi-squared or Fisher’s exact tests for qualitative variables. Concordance was assessed using Cohen κ and was considered as follows: < 0.20 = poor, 0.21–0.40 = fair, 0.41–0.60 = moderate, 0.61–0.80 = good, and 0.81–1.00 = very good. Tests were 2-tailed with a significance level of 5%. Data were analyzed using SPSS v19.0 statistical software.

RESULTS

Of the 227 patients included, 26 (11.5%), 52 (22.9%), and 65 (28.6%) were in VLDA, DAPSA remission, and cDAPSA remission, respectively. Patient demographics and clinical information are given in Table 1. Most of the patients were men (65.4–67.7%) with a mean age from 52.0 to 53.7 years, and mostly had peripheral arthritis (84.6–87.7%). The mean CRP level ranged from 1.9 mg/l to 2.2 mg/l. Familial history of psoriasis was present in 53.8–55.4% of the patients. PsA disease duration was 8.9–9.5 years (Table 1).

View this table:
  • View inline
  • View popup
Table 1.

Demographic and clinical characteristics of the study population.

PsA status at study visit is shown in Table 1. Erosive disease in hands and/or feet was detected in 50.0%, 43.8%, and 41.5% of VLDA, DAPSA ≤ 4, and cDAPSA ≤ 4 patients, respectively. At the study visit, anti-TNF treatment in monotherapy was most frequent in patients with VLDA (42.3% VLDA vs 29.2% DAPSA ≤ 4 and 26.2% DAPSA ≤ 4; Table 2). Conversely, 34.6% of VLDA patients received csDMARD monotherapy compared with 41.7% and 44.6% of DAPSA remission and cDAPSA remission, respectively (Table 2).

View this table:
  • View inline
  • View popup
Table 2.

PsA treatment at study visit.

Table 3 examines the relationship between VLDA and the other indices of remission. There was a moderate agreement between VLDA and DAPSA remission (κ = 0.52) or cDAPSA remission (κ = 0.42).

View this table:
  • View inline
  • View popup
Table 3.

Concordance between VLDA and other indices of remission and PsAID.

Patients with VLDA had less impact of the disease as measured by PsAID [mean total score (SD): VLDA 1.1 (1.2); DAPSA remission 1.3 (1.5); cDAPSA remission 1.7 (1.6); Table 1]. Twenty-five (96.2%) patients with VLDA, 42/52 (80.8%) in DAPSA remission, and 57 (89.1%) in cDAPSA remission obtained a PsAID score < 4. There was moderate agreement between DAPSA or cDAPSA and PsAID < 4 (κ = 0.55 and κ = 0.58, respectively), while poor agreement (κ = 0.18) was found between VLDA and PsAID < 4; Table 3). Figure 1 examines PsAID domains score according to VLDA state, DAPSA remission, and cDAPSA remission. Overall, patients who were in DAPSA remission, and in particular cDAPSA remission, obtained a higher score in all PsAID domains than did patients with VLDA. Only 2 physical domains, fatigue and pain, had a deeper effect on patients with VLDA than on those in DAPSA remission. Statistically significant differences were observed between patients who were in DAPSA and cDAPSA remission or in a VLDA state and those who were not for all PsAID domains (p < 0.001, data not shown).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

PsAID score according to VLDA state, DAPSA remission, and cDAPSA remission. PsAID: Psoriatic Arthritis Impact of Disease; VLDA: very low disease activity; DAPSA: Disease Activity Index for Psoriatic Arthritis; cDAPSA: clinical DAPSA.

DISCUSSION

Remission or low disease activity is the goal of therapy in PsA. In recent years, the development of composite indices tailored for the assessment of PsA disease activity led to the question of which is the best tool for identifying a state of real remission18.

For patients to be in MDA 5/7 is not the same as being in remission, because they may have some residual disease activity3. Studies aimed at comparing the composite indices tailored for PsA showed that VLDA seems to be reliable in assessing a condition of disease remission3,6,18. Data from our present study seem to be in concordance with published data that show that VLDA criteria are among the most stringent for assessing a status of remission5,18. In our study the proportion of patients receiving anti-TNF and/or csDMARD therapy who were in VLDA state (11.5%) was lower than the proportion of those considered in remission state as measured by DAPSA (22.9%) or cDAPSA (28.6%). Recently, a cross-sectional study carried out with 109 patients reported a prevalence of 17.4%, 21.1%, and 25.6% of patients with VLDA, DAPSA remission, and cDAPSA remission state, respectively18. These outcomes were achieved at a higher rate in patients receiving anti-TNF therapy compared with csDMARD18. Lubrano, et al showed a similar rate of patients achieving VLDA criteria and DAPSA remission (37.3% and 36%, respectively) after 12 months of anti-TNF therapy19.

Similar to a previous study19, our results have shown that there is only a moderate relationship between VLDA and DAPSA remission. Although DAPSA is a good instrument for assessing low disease status, some authors have pointed out that its potential weakness is that it is an instrument for evaluating peripheral arthritis only, with a risk of underestimating disease activity in such important domains as skin, axial disease, and enthesitis18. However, although DAPSA includes only joint counts as musculoskeletal manifestations of PsA, it also includes patient pain assessment and PtGA, which might record such other domains as enthesitis and axial disease20.

PsA is a multifaceted chronic inflammatory disease with different manifestations and implications. Patients with PsA experience functional impairment and reduced quality of life, so PtGA in PsA is explained mainly by the physical, but also by the psychological, aspect of the disease21. Patient-reported outcomes, such as the novel PsAID14 questionnaire, are important instruments for evaluating healthcare interventions and for reflecting the effect of PsA on patients’ lives. There are few studies that have reported results with this tool15,21,22.

Recently, we have shown statistically significant differences between MDA and non-MDA patients in all physical and psychological PsAID domains15. As expected, in the present analysis a significantly lesser effect of the disease was also observed for all PsAID domains in patients who were in DAPSA remission or in a VLDA state, compared to those who were not.

Our study shows that patients with VLDA seem have a lower effect of the disease as measured by PsAID as a whole, compared with those in DAPSA remission. In fact, the proportion of patients with a PsAID score < 4 was higher in the VLDA group than in the DAPSA remission groups. However, curiously enough, while poor agreement (κ = 0.18) was found between VLDA and PsAID < 4, it was moderate between DAPSA or cDAPSA and PsAID < 4 (κ = 0.46 and κ = 0.58, respectively). This could explain why fatigue, discomfort, and pain, 3 of the domains predominantly related to physical effect due to joint damage21, achieved the highest scores in patients with VLDA. Skin lesions have a considerable effect on quality of life, particularly in physiological symptoms, but can heal without scarring, while inflammation of the joints has cumulative effects, potentially leading to permanent destruction and impairment of physical function17. Therefore, in this cohort, these symptoms of the disease could carry more weight in the quality of life of the patient. Although DAPSA constitutes an instrument developed primarily to reflect the arthritis aspects of PsA, it correlates very well with functional status and radiological progression of PsA20.

Some limitations derived from the cross-sectional features of this study should be borne in mind. PsA is known to be a heterogeneous disorder, with a highly variable progression between individuals. The data presented here describe a specific moment of the state of illness of patients with a long evolution of the disease.

In our study we report that in normal clinical practice, around 11% and 30% of patients with PsA achieve a VLDA or DAPSA remission state, respectively, which are associated with a low effect of disease (PsAID < 4). Cutaneous and musculoskeletal symptoms could exert different influences on the different PsAID items. However, our results do not allow us to assert a greater weight of the musculoskeletal symptoms in the total PsAID, because the cutaneous involvement in this cohort was very mild. Although moderate agreement exists between VLDA and DAPSA, VLDA criteria seem to be more stringent for assessing a status of remission than are DAPSA ≤ 4. However, DAPSA ≤ 4 seems to reflect better the patients’ point of view of disease.

Acknowledgment

The authors are grateful to Luz Samaniego for her valuable contribution in statistical analyses. We are also grateful to Esther Tapia for helping us with the medical writing of this manuscript.

APPENDIX

List of study collaborators. MAAPS (Minimal Activity in Psoriatic Arthritis) Study Group: J.C. Torre Alonso (H. Monte Naranco, Oviedo, Spain); J.A. Román-Ivorra [Hospital Universitario (HU) La Fe, Valencia, Spain]; J. Sanz (HU Puerta de Hierro, Madrid, Spain); J. Salvatierra (HU San Cecilio, Granada, Spain); J. Calvo-Alén (HU Sierrallana, Torrelavega, Spain); A. Sellas (Vall d’Hebron, Barcelona, Spain); F.J. Rodriguez (Santa Lucia, Cartagena, Spain); A. Bermúdez (Virgen de la Arrixaca, Murcia, Spain); M. Romero (Complejo hospitalario Jaén, Spain); M. Riesco (Rheumatology H. Juan Ramón Jiménez, Huelva, Spain); J.C. Cobeta (H. Royo Villanova, Zaragoza, Spain); F. Medina (H. Puerta del Mar, Cádiz, Spain); A. Aragón (H. Getafe, Madrid, Spain); M.L. García (HU Basurto, Bilbao, Spain); A. Urruticoechea (H. Can Misses, Ibiza, Spain); C.M. González (HU Gregorio Marañón, Madrid, Spain); E. Judez (HU, Albacete, Spain); B. González (HU Nta. Sra de la Candelaria, Tenerife, Spain); P. Fernández (HU 12 de Octubre, Madrid, Spain); L. Pantoja (H. del Bierzo, Leon, Spain); R. Morlá (H. Sant Pau y Sta. Tecla, Tarragona, Spain).

Footnotes

  • This study was funded by Pfizer SLU.

  • Accepted for publication October 16, 2018.

REFERENCES

  1. 1.↵
    1. Chandran V,
    2. Raychaudhuri SP
    . Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 2010;34:J314–21.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Ibrahim G,
    2. Waxman R,
    3. Helliwell PS
    . The prevalence of psoriatic arthritis in people with psoriasis. Arthritis Rheum 2009;61:1373–8.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Coates LC,
    2. Helliwell PS
    . Defining low disease activity states in psoriatic arthritis using novel composite disease instruments. J Rheumatol 2016;43:371–5.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Lubrano E,
    2. Perrotta FM,
    3. Kavanaugh A
    . An overview of low disease activity and remission in psoriatic arthritis. Clin Exp Rheumatol 2015;33:S51–4.
    OpenUrl
  5. 5.↵
    1. van Mens LJ,
    2. van de Sande MG,
    3. van Kuijk AW,
    4. Baeten D,
    5. Coates LC
    . Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort. Ann Rheum Dis 2018;77:251–7.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Coates LC,
    2. Fransen J,
    3. Helliwell PS
    . Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2010;69:48–53.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Coates LC,
    2. Helliwell PS
    . Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res 2010;62:965–9.
    OpenUrlCrossRef
  8. 8.↵
    1. Perrotta FM,
    2. Marchesoni A,
    3. Lubrano E
    . Minimal disease activity and remission in psoriatic arthritis patients treated with anti-TNF-α drugs. J Rheumatol 2016;43:350–5.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Perrotta FM,
    2. Lubrano E
    . Subcutaneous anti-TNF alfa induced sustained minimal disease activity and remission in psoriatic arthritis patients: a retrospective study. Postgrad Med 2016;128:693–6.
    OpenUrl
  10. 10.↵
    1. Haddad A,
    2. Thavaneswaran A,
    3. Ruiz-Arruza I,
    4. Pellett F,
    5. Chandran V,
    6. Cook RJ,
    7. et al.
    Minimal disease activity and anti-tumor necrosis factor therapy in psoriatic arthritis. Arthritis Care Res 2015;67:842–7.
    OpenUrlCrossRef
  11. 11.↵
    1. Schoels MM,
    2. Aletaha D,
    3. Alasti F,
    4. Smolen JS
    . Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis 2016;75:811–8.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Strand V,
    2. Sharp V,
    3. Koenig AS,
    4. Park G,
    5. Shi Y,
    6. Wang B,
    7. et al.
    Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. Ann Rheum Dis 2012;71:1143–50.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Borman P,
    2. Toy GG,
    3. Babaoglu S,
    4. Bodur H,
    5. Ciliz D,
    6. Alli N
    . A comparative evaluation of quality of life and life satisfaction in patients with psoriatic and rheumatoid arthritis. Clin Rheumatol 2007;26:330–4.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Gossec L,
    2. de Wit M,
    3. Kiltz U,
    4. Braun J,
    5. Kalyoncu U,
    6. Scrivo R,
    7. et al;
    8. EULAR PsAID Taskforce
    . A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis 2014;73:1012–9.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Queiro R,
    2. Cañete JD,
    3. Montilla C,
    4. Abad M,
    5. Montoro M,
    6. Gomez S,
    7. et al.
    Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study. Arthritis Res Ther 2017;19:72.
    OpenUrl
  16. 16.↵
    1. Taylor W,
    2. Gladman D,
    3. Helliwell P,
    4. Marchesoni A,
    5. Mease P,
    6. Mielants H;
    7. CASPAR Study Group
    . Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665–73.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Smolen JS,
    2. Schoels M,
    3. Aletaha D
    . Disease activity and response assessment in psoriatic arthritis using the Disease Activity index for PSoriatic Arthritis (DAPSA). A brief review. Clin Exp Rheumatol 2015;5  Suppl 93:S48–50.
    OpenUrl
  18. 18.↵
    1. Lubrano E,
    2. De Socio A,
    3. Perrotta FM
    . Comparison of composite indices tailored for psoriatic arthritis treated with csDMARD and bDMARD: A cross-sectional analysis of a longitudinal cohort. J Rheumatol 2017;44:1159–64.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Lubrano E,
    2. Perrotta FM
    . Defining low disease activity states in psoriatic arthritis using novel composite disease instruments. J Rheumatol 2016;43:1765–6.
    OpenUrlFREE Full Text
  20. 20.↵
    1. Aletaha D,
    2. Alasti F,
    3. Smolen JS
    . Disease activity states of the DAPSA, a psoriatic arthritis specific instrument, are valid against functional status and structural progression. Ann Rheum Dis 2017;76:418–21.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Talli S,
    2. Etcheto A,
    3. Fautrel B,
    4. Balanescu A,
    5. Braun J,
    6. Canete JD,
    7. et al.
    Patient global assessment in psoriatic arthritis - what does it mean? An analysis of 223 patients from the Psoriatic Arthritis Impact of Disease (PsAID) study. Joint Bone Spine 2016;83:335–40.
    OpenUrl
  22. 22.↵
    1. Salaffi F,
    2. Di Carlo M,
    3. Carotti M,
    4. Farah S,
    5. Gutierrez M
    . The Psoriatic Arthritis Impact of Disease 12-item questionnaire: equivalence, reliability, validity, and feasibility of the touch-screen administration versus the paper-and-pencil version. Ther Clin Risk Manag 2016;12:631–42.
    OpenUrl
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 46, Issue 7
1 Jul 2019
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Very Low Disease Activity, DAPSA Remission, and Impact of Disease in a Spanish Population with Psoriatic Arthritis
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Very Low Disease Activity, DAPSA Remission, and Impact of Disease in a Spanish Population with Psoriatic Arthritis
Ruben Queiro, Juan D. Cañete, Carlos Montilla, Miguel Angel Abad, María Montoro, Susana Gómez, Ana Cábez
The Journal of Rheumatology Jul 2019, 46 (7) 710-715; DOI: 10.3899/jrheum.180460

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Very Low Disease Activity, DAPSA Remission, and Impact of Disease in a Spanish Population with Psoriatic Arthritis
Ruben Queiro, Juan D. Cañete, Carlos Montilla, Miguel Angel Abad, María Montoro, Susana Gómez, Ana Cábez
The Journal of Rheumatology Jul 2019, 46 (7) 710-715; DOI: 10.3899/jrheum.180460
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgment
    • APPENDIX
    • Footnotes
    • REFERENCES
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters

Keywords

DISEASE ACTIVITY
REMISSION
PSORIATIC ARTHRITIS
DISEASE ACTIVITY CRITERIA

Related Articles

Cited By...

More in this TOC Section

  • Canadian Adalimumab Postmarketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis (COMPLETE-PsA): 12-month Results of Comparative Effectiveness of Adalimumab and nbDMARDs
  • Evaluation of Clinical Diagnosis of Axial Psoriatic Arthritis (PsA) or Elevated Patient-reported Spine Pain in CorEvitas’ PsA/Spondyloarthritis Registry
  • The Association of Psoriatic Arthritis With All-cause Mortality and Leading Causes of Death in Psoriatic Arthritis
Show more Psoriatic Arthritis

Similar Articles

Keywords

  • disease activity
  • remission
  • psoriatic arthritis
  • DISEASE ACTIVITY CRITERIA

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire